Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus Boyle PJ; Freeman JSJ Am Osteopath Assoc 2007[May]; 107 Suppl (ä): S10-6Approximately two thirds of patients with type 2 diabetes mellitus (T2DM) are unable to reach the hemoglobin A(1c) target set by the American Diabetes Association (HbA(1c) <7.0%). Therefore, T2DM continues to be a major public health concern. Incretin mimetics and dipeptidyl peptidase IV inhibitors are medications that have the potential to improve patients' glycemic control, as well as to result in beneficial socioeconomic effects. Research suggests that significant benefits are to be gained from incretin mimetics and dipeptidyl peptidase IV inhibitors, either one used as monotherapy or used together as combination therapy. However, the benefits and risks of these agents need to be evaluated more thoroughly, with emphasis on such adverse effects as edema, hypoglycemia, and weight gain.|*Dipeptidyl-Peptidase IV Inhibitors[MESH]|Diabetes Mellitus, Type 2/*drug therapy/physiopathology[MESH]|Dipeptidyl Peptidase 4/therapeutic use[MESH]|Dose-Response Relationship, Drug[MESH]|Drug Administration Schedule[MESH]|Exenatide[MESH]|Female[MESH]|Gastric Inhibitory Polypeptide/therapeutic use[MESH]|Glucagon-Like Peptide 1/*analogs & derivatives/therapeutic use[MESH]|Humans[MESH]|Hyperglycemia/drug therapy[MESH]|Hypoglycemic Agents/therapeutic use[MESH]|Liraglutide[MESH]|Male[MESH]|Peptides/*therapeutic use[MESH]|Probability[MESH]|Prognosis[MESH]|Treatment Outcome[MESH]|Venoms/*therapeutic use[MESH] |
